Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors : KEYNOTE-158
Aim: To evaluate pembrolizumab in patients of Chinese descent with microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) tumors enrolled in KEYNOTE-158 (Cohort L). Methods: Patients with MSI-H/dMMR advanced tumors received pembrolizumab 200 mg IV Q3W. Primary end point was overall response rate (ORR). Secondary end points were duration of response (DOR), progression-free survival (PFS) and overall survival (OS). Results: 24 patients were enrolled (20 were evaluable for efficacy). With median follow-up of 12.4 months, the ORR was 70%. DOR, PFS and OS were all not reached. A total of 19 (79%) patients had a treatment-related adverse event (AE; grade ≥3 in 4 [17%]), and 8 (33%) had an immune-mediated AE (grade ≥3 in (4 [17%]). Conclusion: Pembrolizumab provided meaningful and durable responses with manageable safety. These results are consistent with those reported for the global trial.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Immunotherapy - (2024) vom: 20. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xu, Jianming [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Agnostic |
|---|
| Anmerkungen: |
Date Revised 20.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2217/imt-2023-0294 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369958586 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369958586 | ||
| 003 | DE-627 | ||
| 005 | 20240320235628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/imt-2023-0294 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM369958586 | ||
| 035 | |a (NLM)38506258 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Jianming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors |b KEYNOTE-158 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Aim: To evaluate pembrolizumab in patients of Chinese descent with microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) tumors enrolled in KEYNOTE-158 (Cohort L). Methods: Patients with MSI-H/dMMR advanced tumors received pembrolizumab 200 mg IV Q3W. Primary end point was overall response rate (ORR). Secondary end points were duration of response (DOR), progression-free survival (PFS) and overall survival (OS). Results: 24 patients were enrolled (20 were evaluable for efficacy). With median follow-up of 12.4 months, the ORR was 70%. DOR, PFS and OS were all not reached. A total of 19 (79%) patients had a treatment-related adverse event (AE; grade ≥3 in 4 [17%]), and 8 (33%) had an immune-mediated AE (grade ≥3 in (4 [17%]). Conclusion: Pembrolizumab provided meaningful and durable responses with manageable safety. These results are consistent with those reported for the global trial | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chinese descent | |
| 650 | 4 | |a MSI-H | |
| 650 | 4 | |a agnostic | |
| 650 | 4 | |a dMMR | |
| 650 | 4 | |a pembrolizumab | |
| 700 | 1 | |a Mao, Yimin |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Nong |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Yuxian |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaojun |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Xianli |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Yanhong |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jianwei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jieqing |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jiayi |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Suxia |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Weidong |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Miaomiao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Yixiang |e verfasserin |4 aut | |
| 700 | 1 | |a Gozman, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Xiaohua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunotherapy |d 2009 |g (2024) vom: 20. März |w (DE-627)NLM19257163X |x 1750-7448 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:20 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/imt-2023-0294 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 20 |c 03 | ||